GSK shutting down Biopolis neural unit
Other ongoing investments here not affected; UK pharma giant remains committed to R&D in Singapore
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
IN a move to cut costs, United Kingdom pharma giant GlaxoSmithKline (GSK) will begin a phased closure of its operations at its neural pathways discovery performance unit at Biopolis, following its global review to refocus the global pharmaceuticals business.
While it declined to reveal the number of employees affected by the closure, the drugmaker, which employs 1,700 people here, said it remains committed to research and development (R&D) in Singapore, which is a "a key location for GSK's global manufacturing and commercial operations".
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
